ECOR:NASDAQelectroCore, Inc. Analysis
Data as of 2026-05-26 - not real-time
$6.67
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
electroCore, Inc. (ECOR) is trading just above its 20‑day and 50‑day SMAs at around $6.70, with a neutral trend and an RSI in the mid‑50s, suggesting no immediate overbought or oversold condition. Technical momentum is mixed – the MACD histogram is negative and the MACD line sits below its signal, hinting at short‑term bearish pressure, while volume is on the rise and the stock sits well above its recent support of $5.70.
Fundamentally, the company posted a 43% jump in Q1 revenue to $9.6 million and maintains an impressive 87% gross margin, yet it continues to generate sizable losses, negative operating cash flow, and a net cash deficit after debt. Analysts are highly optimistic, rating the stock a strong buy with median price targets near $20, translating to an implied upside of well over 150%. The market sentiment is extremely greedy, but the stock’s high beta (~2.3) and 30‑day volatility above 60% elevate both market‑related and liquidity risks.
Fundamentally, the company posted a 43% jump in Q1 revenue to $9.6 million and maintains an impressive 87% gross margin, yet it continues to generate sizable losses, negative operating cash flow, and a net cash deficit after debt. Analysts are highly optimistic, rating the stock a strong buy with median price targets near $20, translating to an implied upside of well over 150%. The market sentiment is extremely greedy, but the stock’s high beta (~2.3) and 30‑day volatility above 60% elevate both market‑related and liquidity risks.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD momentum despite rising volume
- Price marginally above short‑term moving averages
- High short‑term volatility and beta
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth and high gross margin
- Analyst consensus of strong‑buy with lofty price targets
- Undervalued price relative to implied upside
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Potential to achieve profitability as cash burn moderates
- Expanding product pipeline in the bioelectronic medicine space
- Sustained market enthusiasm reflected in extreme greed sentiment
Key Metrics & Analysis
Financial Health
Revenue Growth42.60%
Profit Margin-44.08%
P/E Ratio-12.1
ROA-58.08%
P/B Ratio-9.5
Op. Cash Flow$-6840000
Free Cash Flow$-869750
Industry P/E27.6
Technical Analysis
TrendNeutral
RSI55.2
Support$5.70
Resistance$7.34
MA 20$6.37
MA 50$6.38
MA 200$5.70
MACDBearish
VolumeIncreasing
Fear & Greed Index91.8
Valuation
Target Price$19.17
Upside/Downside187.41%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta2.28
Volatility60.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.